Baricitinib (also known as LY3009104 or INCB028050) is a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2. Baricitinib is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.
Baricitinib is already in Phase III for RA and in Phase II for psoriasis and diabetic nephropathy.
View Contact Detail